PRF Technologies vs Talphera
PRFX and TLPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRFX and TLPH compare
PRF Technologies keeps more of each dollar of sales as profit, with a net margin of −29541% compared with −1507600% at Talphera.
PRF Technologies scores higher on the StockData Score (6 against 5 for Talphera), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRFX | TLPH |
|---|---|---|
| Size and price | ||
| Market cap | – | $44.7M |
| Share price | $0.695 | $0.861 |
| Change, 1 year | −85.1% | −18.0% |
| Change, 5 years | −99.9% | −93.4% |
| Beta (5Y) | 3.63 | 1.19 |
| Employees | 6 | 12 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 44686× |
| P/B | – | 3.1× |
| Growth | ||
| Revenue growth (TTM) | – | −96.3% |
| Revenue growth, 5Y average | – | −65.1% |
| Profitability | ||
| Gross margin | −312% | – |
| Operating margin | −30129% (better) | −1474700% |
| Net margin | −29541% (better) | −1507600% |
| FCF margin | −23277% | – |
| Return on equity | −41.3% (better) | −143% |
| Return on invested capital | −87.0% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.07 (better) | 4.29 |
| Altman Z-score | – | −24.02 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 24.5% | 54.4% |
| Held by insiders | 24.1% | 46.8% |
| Insider net buying, 12 months | – | $304K |
| Short interest, % of float | 2.0% | 4.4% |
Go deeper
- PRFX stock overview
- PRFX income statement
- PRFX valuation and score
- TLPH stock overview
- TLPH income statement
- TLPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.